Call us at 0086-13916539828

News Detail

Welcome to our website!

Termofisher Launches New Oncomine Tumor Reagents for Helping Immunotherapy Research

2018-12-21 16:51:09

Recently, the real-life domestic film "Drug God" has earned the tears of the audience. The bumpy course of cancer patients seeking medical treatment has hurt the hearts of countless people.

In fact, in the face of the mountain of cancer, humanity has never stopped exploring, and every breakthrough in medical technology has made us one step closer to the "cancer-free world."


Nowadays, we have made important breakthroughs in the journey of exploration. What is the significance of the latest OncomineTCR Beta-SR Assay reagent for tumor immunology research? Thermo Fisher gave a good answer.


Recently, Thermo Fisher Scientific, the world leader in scientific services, announced the launch of Oncomine TCR Beta-SR Assay (SR = Short Reads) reagent based on High Throughput Sequencing Technology (NGS). The product can be used to comprehensively assess the diversity of the immune system, to evaluate the body's immune response to infection, vaccines, cellular immunotherapy, to reflect the relationship between the immune library and disease and treatment, and to further explore the potential markers associated with immune response. The launch of Oncomine TCR Beta-SR Assay further complements Thermo Scientific's T-cell immune library solution, which is compatible with blood, FFPE (paraffin-embedded tissue), and cfDNA samples, and further reduces primer interference with dual-barcode technology. Errors and improved detection sensitivity are conducive to the continuous development of tumor immunology research.


In recent years, tumor cell therapy represented by stem cell therapy and CAR-T (chimeric antigen receptor T cell immunotherapy) immune cell therapy has become one of the directions leading the future medical revolution, and has attracted attention in the industry. With the deepening of relevant research, the T cell immune group has gradually become a hot spot and breakthrough in tumor immunotherapy and cell therapy research. In 2017, Thermo Fisher launched the TCR immunoassay library to detect NGS reagents (Oncomine TCR Beta-LR Assay). The on-line Oncomine TCR Beta-SR Assay complements the previously announced Oncomine TCR Beta-LR Assay to further complement its T-cell immune library solution.


The unique design of Oncomine TCR Beta-SRAssay allows researchers to select DNA or RNA as a starting sample for detection without interference from primer bias. The researchers can analyze within 48 hours using the Ion GeneStudio S5 system and the Ion Torrent analysis system. result. When used in conjunction with the Oncomine TCR Beta-LR Assay, researchers can perform comprehensive TCR beta sequencing, obtaining typing results including the TRBV allele, clonal analysis for immune response, and engineered T cell monitoring.


Tony Acciarito, president of Thermo Fisher in Greater China, said:


Supporting tumor immunotherapy research is one of the key business activities of Thermo Scientific in the field of biomedicine in recent years. We hope to further improve our T cell immune library solution by listing on the Oncomine TCR Beta-SR Assay to help us in all aspects. The client accelerates the clinical transformation of tumor immunotherapy and fulfills the mission of Thermo Fisher to make the world healthier.


Shanghai Yuke sells Termofisher experimental equipment, providing laboratory automation equipment and providing system solutions according to user requirements.